Is a Press Release Job Safety for Pharma PR Managers?

Much has been made about the viability of social media in the world of pharma. On this blog, we have explored both the challenges of social media for pharma companies and the challenges of traditional PR. In the year since that original post was written, significant strides have been made and pharma companies are beginning to dip their toes in the social media water. The question is: why now?
Surely, the same challenges that were present a year ago still exist today. Corporate bureaucracy? Check. Heavy regulatory issues? Check. Sensitive topics? Check. Questionable reputations? Check. The pharmaceutical industry is so wrought with roadblocks and landmines that few companies have mustered the courage to test the water. In tech, the saying goes: “No CIO was ever fired for purchasing Cisco.” Well for PR managers at pharma companies, perhaps the saying should go: “No PR manager was ever fired for issuing a press release.” But as evidenced by the efforts of companies like J&J, GSK, The Mayo Clinic and Pfizer (to name a few), healthcare companies are growing less wary of jumping into the mix.
So why the steady shift toward social media for pharma companies? For starters, pharma companies may finally be coming to the painful realization that tried and true methods of marketing are no longer effective. Consumers have grown tired of the onslaught of ads touting the next great drug for hair loss. For too long, marketers in the healthcare industry have relied on highly impersonal forms of marketing for issues that are the exact opposite. Even traditional PR efforts have lost some luster with the average consumer. It is no wonder then that pharma companies are seeking new ways to engage with the patient.
In some respects, it is surprising that it has taken this long for pharma companies to come around. When you think of the benefits of social media—direct engagement with the consumer, a captive and targeted audience, a group with similar interests, etc…—social media is perfectly suited for pharma companies. This is primarily because there are few industries that deal with issues as personal as a healthcare company. Sure, you might be emotionally invested in the next purchase of your iPhone or car, but few things make as significant an impact on an individual’s life as health. This personal nature is what has rightfully brought heavy-handed regulation on the industry. It is also this personal nature that has scared many marketers away. But, this personal nature is EXACTLY why pharmaceutical companies should be embracing social media—not shunning it. Social media engagement provides those companies with the ability to get past expensive advertising campaigns and to fully engage with their consumer. Why not become a part of communities focused on managing diseases better or living a healthy lifestyle? People tend to congregate online around issues they care deeply about—and health is certainly chief among those issues. The risks of engaging at this level are real and should not be overlooked. And of course, any social media efforts should be carefully planned and only done with the utmost transparency—devoid of any sense of exploitation.
If the efforts of some of these early leaders is any indication—the pharma industry might just be coming around.



